Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Realgar indigo formula plus retinoic acid as post-remission treatment for high-risk acute promyelocytic leukemia
ChiCTR1900023309Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Compound Huangdai Tablet and tretinoin in Acute promyelocytic leukaemia (APL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Disease-free survival. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
Compound Huangdai Tablettretinoin
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR1900023309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023309.